News | October 02, 2014

ESC Abstracts Show Utility of Singulex's Troponin, Renal Function Tests

October 2, 2014 — Singulex Inc. announced the presentation of 10 abstracts at the European Society of Cardiology's (ESC) annual conference, which highlight the clinical utility of single molecule counting technology in the detection and quantification of biomarkers for cardiac disease, its comorbidities, and its risk factors. The conference, held in Barcelona, Spain from Aug. 30 through Sept. 3rd, also featured the first European preview of the Sgx Clarity System, a fully-automated, SMC-powered in vitrodiagnostics system targeted for launch to European hospitals and reference labs in 2016.

Three of the 10 abstracts accepted by ESC Congress 2014 were selected for oral presentations:

Ultra-sensitive troponin I strongly predicts incident coronary heart disease in the general population independently of traditional risk factors. Results from the MONICA/KORA Augsburg Case-Cohort Study
Wolfgang Koenig, M.D., Ph.D., professor of medicine/cardiology at the department of internal medicine II — cardiology at the University of Ulm Medical School, Ulm, Germany, reported that even modestly increased cardiac Troponin I (cTnI) levels are strongly associated with incident coronary heart disease (CHD) independent of standard risk factors. Using Singulex's highly sensitive cTnI research-use-only immunoassay, the long-term, population-based, prospective study found that cTnI was detectable in almost every healthy middle-aged subject. Incident CHD subjects had a higher baseline cTnI level than subjects who did not develop CHD (geometric mean 2.56 vs. 1.49 ng/L, p<0.0001).

"Singulex's highly-sensitive cTnI assay has enabled us to predict the incidence of coronary heart disease in the general population," stated Koenig. "I believe we now have the ability to gain greater insight into the cardiovascular risk profile of individuals who have not already been diagnosed with the disease."

Incremental value of single resting ultrasensitive cardiac Troponin I measurement to rule-out myocardial ischemia
Yunus Tanglay, M.D., department of cardiology, Cardiovascular Research Institute Basel, University Hospital Basel, Basel, Switzerland, presented the results of a study that determined that cTnI levels complement non-invasive clinical assessments in patients with suspected coronary artery disease (CAD). cTnI levels were measured using Singulex's highly sensitive cTnI research-use-only immunoassay in 714 patients without known CAD before and after a bicycle exercise stress-test. Myocardial ischemia (MIS) was detected in 167 (23.4%) patients, and cTnI levels were significantly higher in patients with MIS (4.0 ng/L [95% CI 2.8-8.6] vs. 2.6 ng/L [95% CI 1.8-4.1], p<0.001). Diagnostic accuracy of CAD increased when both clinical judgment and cTnI levels were considered prior to a patient's stress test.

Plasma Kidney Injury Molecule (KIM-1) and Endothelin-1 (ET-1) are associated with worsening renal function in Heart Failure patients
Eitan Friedman, M.D., division of cardiovascular medicine, Vanderbilt University Medical Center, Nashville, Tenn., stated that this study was the first to demonstrate that KIM-1 was not only quantifiable in plasma, but also serves as a biomarker for worsening renal function in heart failure (HF) patients. Elevation in urinary KIM-1 is a known indication of renal tubule epithelial damage, however, this study was the first to establish the biomarker's utility in plasma. ET-1, a low abundance, known plasma biomarker of endothelial function, was also found to be independently associated with worsening kidney function in HF patients. Renal dysfunction is a comorbidity of HF.

The following abstracts were presented in a poster presentation:

  • The clinical benefit of ultrasensitive cardiac Troponin I in the detection of exercise-induced myocardial ischemia
  • Novel dual-biomarker strategy and clinical judgment in the detection of exercise-induced myocardial ischemia
  • Subclinical inflammation quantified by Interleukin-6 for detection of exercise-induced myocardial ischemia
  • Cardiac Biomarkers pMMP-9, IL-6, and ET-1 are elevated in asymptomatic patients at risk of heart failure and associate with disease severity
  • Plasma Kidney Injury Molecule (KIM-1) and Endothelin-1 (ET-1) are associated with worsening renal function in Heart Failure patients
  • Glucagon like peptide-1 and blood pressure in young, healthy adults: a population-based study
  • Plasma glucagon-like-peptide 1 and body fat mass among young and healthy adults
  • Plasma endothelin-1 and risk of obstructive sleep apnea among young and healthy adults

Commenting on the significance of the abstract findings presented at the Congress, Guido Baechler, president and CEO of Singulex, stated, "Cardiovascular disease is the leading cause of death in the European Union, and thanks to our academic collaborators, we are even more confident that our SMC technology can offer a means to better detect, assess, and manage CVD patients, along- with associated comorbidities and risk factors. As these study findings indicate, with the launch of the SMC technology-based Sgx Clarity System in 2016, European physicians will have at their disposal a powerful diagnostic tool and unique portfolio of tests to drive evidence-based management of patients and improved outcomes."

For more information: visit

Related Content

FDA Clears Abbott's High Sensitivity Troponin-I Blood Test
Technology | Blood Testing | October 09, 2019
Abbott recently announced that its Architect Stat High Sensitivity Troponin-I blood test has received clearance from...
Rapid Diagnosis Protocol for Chest Pain Does Not Improve Outcomes
News | Blood Testing | September 18, 2019
Discharge of patients with suspected acute coronary syndromes under a 0- and 1-hour high-sensitivity cardiac troponin T...
Validation Studies Confirm High Accuracy of Novel HART AI-Driven Blood Tests
News | Blood Testing | March 19, 2019
Prevencio Inc. announced data confirming the high accuracy of its artificial intelligence (AI)-driven, multiple-protein...
CoaguChek XS PT Test Strips Recalled for Inaccurately Reporting High INR
News | Blood Testing | December 28, 2018
Terrific Care LLC. / Medex Supply Dist Inc. initiated a nationwide recall on Dec. 19 of Roche CoaguChek test strips, as...
Abbott Point-of-Care Blood Test Speeds Heart Attack Diagnosis
News | Blood Testing | October 26, 2018
For someone experiencing cardiac symptoms in the emergency room, every minute matters as physicians determine whether...
New Noninvasive Blood Glucose Test as Effective as Finger Prick

Image courtesy of University of Missouri School of Medicine

News | Blood Testing | October 24, 2018
For those living with diabetes, monitoring blood glucose accurately is necessary to prevent diabetes-related...
Abbott Receives CE Mark for High Sensitive Troponin-I Test
News | Blood Testing | October 16, 2018
October 16, 2018 — Abbott announced that its High Sensitive Troponin-I...
AI-Driven Blood Test Accurately Diagnoses Peripheral Artery Disease in Diabetic Patient
News | Blood Testing | September 04, 2018
Prevencio Inc. announced new data demonstrating its HART PAD test accurately diagnoses peripheral artery disease (PAD)...
More Sensitive Blood Test Diagnoses Heart Attacks Faster
News | Blood Testing | August 06, 2018
August 6, 2018 — A new test to assess a whether or not someone is having a...
Singulex cTnl Assay Can Identify Presence, Severity of CAD in Stable, Symptomatic Outpatients
News | Blood Testing | March 26, 2018
March 26, 2018 — Measurement of cardiac troponin in stable patients with chest pain using the ultra-sensitive Singule